| Year |
Citation |
Score |
| 2024 |
Goddard ET, Linde MH, Srivastava S, Klug G, Shabaneh TB, Iannone S, Grzelak CA, Marsh S, Riggio AI, Shor RE, Linde IL, Guerrero M, Veatch JR, Snyder AG, Welm AL, et al. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell. 42: 119-134.e12. PMID 38194912 DOI: 10.1016/j.ccell.2023.12.011 |
0.311 |
|
| 2023 |
Cannon-Albright LA, Stevens J, Teerlink CC, Facelli JC, Allen-Brady K, Welm AL. A Rare Variant in (rs111879470) Is Associated with Predisposition to Recurrent Breast Cancer in an Extended High-Risk Pedigree. Cancers. 15. PMID 38136396 DOI: 10.3390/cancers15245851 |
0.393 |
|
| 2023 |
Wu Y, Chen S, Yang X, Sato K, Lal P, Wang Y, Shinkle AT, Wendl MC, Primeau TM, Zhao Y, Gould A, Sun H, Mudd JL, Hoog J, Mashl RJ, ... ... Welm AL, et al. Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. Cancer Research. 83: 4161-4178. PMID 38098449 DOI: 10.1158/0008-5472.CAN-23-0604 |
0.359 |
|
| 2023 |
Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, ... ... Welm AL, et al. Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer. Cancer Research. PMID 37450351 DOI: 10.1158/0008-5472.CAN-23-1711 |
0.479 |
|
| 2023 |
Quail DF, Park M, Welm AL, Ekiz HA. Breast Cancer Immunity: It is TIME for the Next Chapter. Cold Spring Harbor Perspectives in Medicine. PMID 37188526 DOI: 10.1101/cshperspect.a041324 |
0.484 |
|
| 2022 |
Petrosyan V, Dobrolecki LE, LaPlante EL, Srinivasan RR, Bailey MH, Welm AL, Welm BE, Lewis MT, Milosavljevic A. Immunologically "cold" triple negative breast cancers engraft at a higher rate in patient derived xenografts. Npj Breast Cancer. 8: 104. PMID 36088362 DOI: 10.1038/s41523-022-00476-0 |
0.466 |
|
| 2022 |
Nandi A, Debnath R, Nayak A, To TKJ, Thacker G, Reilly M, Gumber S, Karagounis I, Li N, Lengner CJ, Haldar M, Welm AL, Blanco MA, Thomas C, Chakrabarti R. Dll1-mediated Notch signaling drives tumor cell crosstalk with cancer associated fibroblasts to promote radioresistance in breast cancer. Cancer Research. PMID 36007109 DOI: 10.1158/0008-5472.CAN-21-1225 |
0.518 |
|
| 2022 |
Hoover AR, Liu K, DeVette CI, Krawic JR, Medcalf AD, West CL, Hode T, Lam SSK, Welm AL, Sun XH, Hildebrand WH, Chen WR. Single-cell RNA sequencing reveals localized tumour ablation and intratumoural immunostimulant delivery potentiate T cell mediated tumour killing. Clinical and Translational Medicine. 12: e937. PMID 35808806 DOI: 10.1002/ctm2.937 |
0.361 |
|
| 2022 |
Kumar S, Nandi A, Singh S, Regulapati R, Li N, Tobias JW, Siebel CW, Blanco MA, Klein-Szanto AJ, Lengner C, Welm AL, Kang Y, Chakrabarti R. Author Correction: Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway. Nature Communications. 13: 3927. PMID 35798701 DOI: 10.1038/s41467-022-30946-9 |
0.431 |
|
| 2022 |
Stires H, Bado I, Brown T, Carlson M, Chan IS, Echeverria GV, Ewald AJ, Lim B, Lloyd C, Maues J, Oesterreich S, Riter RN, Shanahan K, Welm AL, Newby J. Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research. Npj Breast Cancer. 8: 75. PMID 35773258 DOI: 10.1038/s41523-022-00440-y |
0.344 |
|
| 2022 |
Knudsen ES, Kumarasamy V, Nambiar R, Pearson JD, Vail P, Rosenheck H, Wang J, Eng K, Bremner R, Schramek D, Rubin SM, Welm AL, Witkiewicz AK. CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities. Cell Reports. 38: 110448. PMID 35235778 DOI: 10.1016/j.celrep.2022.110448 |
0.355 |
|
| 2022 |
Guillen KP, Fujita M, Butterfield AJ, Scherer SD, Bailey MH, Chu Z, DeRose YS, Zhao L, Cortes-Sanchez E, Yang CH, Toner J, Wang G, Qiao Y, Huang X, Greenland JA, ... ... Welm AL, et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nature Cancer. 3: 232-250. PMID 35221336 DOI: 10.1038/s43018-022-00337-6 |
0.403 |
|
| 2021 |
Dai J, Cimino PJ, Gouin KH, Grzelak CA, Barrett A, Lim AR, Long A, Weaver S, Saldin LT, Uzamere A, Schulte V, Clegg N, Pisarsky L, Lyden D, Bissell MJ, ... ... Welm AL, et al. Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain. Nature Cancer. 3: 25-42. PMID 35121993 DOI: 10.1038/s43018-021-00297-3 |
0.378 |
|
| 2021 |
Scherer SD, Riggio AI, Haroun F, DeRose YS, Ekiz HA, Fujita M, Toner J, Zhao L, Li Z, Oesterreich S, Samatar AA, Welm AL. An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer. Breast Cancer Research : Bcr. 23: 100. PMID 34717714 DOI: 10.1186/s13058-021-01476-x |
0.453 |
|
| 2021 |
Chew NJ, Lim Kam Sian TCC, Nguyen EV, Shin SY, Yang J, Hui MN, Deng N, McLean CA, Welm AL, Lim E, Gregory P, Nottle T, Lang T, Vereker M, Richardson G, et al. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models. Breast Cancer Research : Bcr. 23: 82. PMID 34344433 DOI: 10.1186/s13058-021-01461-4 |
0.452 |
|
| 2021 |
Lai SA, Gundlapalli H, Ekiz HA, Jiang A, Fernandez E, Welm AL. Blocking short-form Ron eliminates breast cancer metastases through accumulation of stem-like CD4+ T cells that subvert immunosuppression. Cancer Discovery. PMID 34330779 DOI: 10.1158/2159-8290.CD-20-1172 |
0.53 |
|
| 2021 |
Puvvula PK, Yu Y, Sullivan KR, Eyob H, Rosenberg J, Welm A, Huff C, Moon AM. Inhibiting an RBM39/MLL1 epigenomic regulatory complex with dominant-negative peptides disrupts cancer cell transcription and proliferation. Cell Reports. 35: 109156. PMID 34077726 DOI: 10.1016/j.celrep.2021.109156 |
0.746 |
|
| 2021 |
Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, ... ... Welm AL, et al. Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics. PMID 33608693 DOI: 10.1038/s41588-021-00811-4 |
0.3 |
|
| 2021 |
Viswanath P, Welm AL. Heterogeneity in Metastatic Potential of Cancer Cells Is Revealed En Masse. Cancer Cell. 39: 148-150. PMID 33561396 DOI: 10.1016/j.ccell.2021.01.017 |
0.444 |
|
| 2021 |
Kumar S, Nandi A, Singh S, Regulapati R, Li N, Tobias JW, Siebel CW, Blanco MA, Klein-Szanto AJ, Lengner C, Welm AL, Kang Y, Chakrabarti R. Dll1 quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway. Nature Communications. 12: 432. PMID 33462238 DOI: 10.1038/s41467-020-20664-5 |
0.527 |
|
| 2021 |
Dhimolea E, de Matos Simoes R, Kansara D, Al'Khafaji A, Bouyssou J, Weng X, Sharma S, Raja J, Awate P, Shirasaki R, Tang H, Glassner BJ, Liu Z, Gao D, Bryan J, ... ... Welm A, et al. An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. Cancer Cell. PMID 33417832 DOI: 10.1016/j.ccell.2020.12.002 |
0.451 |
|
| 2021 |
Welm BE, Vaklavas C, Welm AL. Toward improved models of human cancer. Apl Bioengineering. 5: 010901. PMID 33415312 DOI: 10.1063/5.0030534 |
0.348 |
|
| 2021 |
Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, ... ... Welm AL, et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics. 53: 86-99. PMID 33414553 DOI: 10.1038/s41588-020-00750-6 |
0.357 |
|
| 2020 |
Zarei O, Faham N, Vankayalapati H, Raeppel SL, Welm AL, Hamzeh-Mivehroud M. Ligand-based Discovery of Novel Small Molecule Inhibitors of RON Receptor Tyrosine Kinase. Molecular Informatics. PMID 33274845 DOI: 10.1002/minf.202000181 |
0.306 |
|
| 2020 |
Dustin D, Gu G, Beyer AR, Herzog SK, Edwards DG, Lin H, Gonzalez TL, Grimm SL, Coarfa C, Chan DW, Kim BJ, De La O JP, Ellis MJ, Liu D, Li S, ... Welm AL, et al. RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. British Journal of Cancer. PMID 33257837 DOI: 10.1038/s41416-020-01174-z |
0.432 |
|
| 2020 |
Zoeller JJ, Vagodny A, Daniels VW, Taneja K, Tan BY, DeRose YS, Fujita M, Welm AL, Letai A, Leverson JD, Blot V, Bronson RT, Dillon DA, Brugge JS. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer. Breast Cancer Research : Bcr. 22: 132. PMID 33256808 DOI: 10.1186/s13058-020-01374-8 |
0.326 |
|
| 2020 |
Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. British Journal of Cancer. PMID 33239679 DOI: 10.1038/s41416-020-01161-4 |
0.433 |
|
| 2020 |
Tavora B, Mederer T, Wessel KJ, Ruffing S, Sadjadi M, Missmahl M, Ostendorf BN, Liu X, Kim JY, Olsen O, Welm AL, Goodarzi H, Tavazoie SF. Tumoural activation of TLR3-SLIT2 axis in endothelium drives metastasis. Nature. PMID 32999457 DOI: 10.1038/s41586-020-2774-y |
0.405 |
|
| 2020 |
Song K, Cai X, Dong Y, Wu H, Wei Y, Shankavaram U, Cui K, Lee Y, Zhu B, Bhattacharjee S, Wang B, Zhang K, Wen A, Wong S, Yu L, ... ... Welm AL, et al. Epsins 1 and 2 promote NEMO linear ubiquitination via LUBAC to drive breast cancer development. The Journal of Clinical Investigation. PMID 32960814 DOI: 10.1172/JCI129374 |
0.452 |
|
| 2020 |
DeVette CI, Gundlapalli H, Lai SA, McMurtrey CP, Hoover AR, Gurung HR, Chen WR, Welm AL, Hildebrand WH. A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer. Oncoimmunology. 9: 1685300. PMID 32002300 DOI: 10.1080/2162402X.2019.1685300 |
0.45 |
|
| 2019 |
Palomeras S, Diaz-Lagares Á, Viñas G, Setien F, Ferreira HJ, Oliveras G, Crujeiras AB, Hernández A, Lum DH, Welm AL, Esteller M, Puig T. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer. Breast Cancer Research : Bcr. 21: 79. PMID 31277676 DOI: 10.1186/S13058-019-1160-X |
0.318 |
|
| 2019 |
Zijlstra A, Von Lersner A, Yu D, Borrello L, Oudin M, Kang Y, Sahai E, Fingleton B, Stein U, Cox TR, Price JT, Kato Y, Welm AL, Aguirre-Ghiso JA. The importance of developing therapies targeting the biological spectrum of metastatic disease. Clinical & Experimental Metastasis. PMID 31102066 DOI: 10.1007/S10585-019-09972-3 |
0.41 |
|
| 2019 |
Kinsey CG, Camolotto SA, Boespflug AM, Gullien KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW, Cavalieri CC, ... ... Welm AL, et al. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature Medicine. PMID 30833748 DOI: 10.1038/S41591-019-0367-9 |
0.414 |
|
| 2018 |
Fornetti J, Welm AL, Stewart SA. Understanding the Bone in Cancer Metastasis. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. PMID 30476357 DOI: 10.1002/jbmr.3618 |
0.425 |
|
| 2018 |
Faham N, Zhao L, Welm AL. mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential. Npj Breast Cancer. 4: 36. PMID 30456298 DOI: 10.1038/s41523-018-0091-5 |
0.564 |
|
| 2018 |
Ekiz HA, Lai SA, Gundlapalli H, Haroun F, Williams MA, Welm AL. Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth. Oncoimmunology. 7: e1480286. PMID 30228950 DOI: 10.1080/2162402X.2018.1480286 |
0.503 |
|
| 2018 |
Toosi BM, El Zawily A, Truitt L, Shannon M, Allonby O, Babu M, DeCoteau J, Mousseau D, Ali M, Freywald T, Gall A, Vizeacoumar FS, Kirzinger MW, Geyer CR, Anderson DH, ... ... Welm AL, et al. EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours. Oncogene. PMID 29700392 DOI: 10.1038/s41388-018-0228-x |
0.399 |
|
| 2018 |
DeVette CI, Andreatta M, Bardet W, Cate SJ, Jurtz VI, Jackson KW, Welm AL, Nielsen M, Hildebrand WH. NetH2pan: A Computational Tool to Guide MHC peptide prediction on Murine Tumors. Cancer Immunology Research. PMID 29615400 DOI: 10.1158/2326-6066.Cir-17-0298 |
0.346 |
|
| 2018 |
Sun Q, Lesperance J, Wettersten H, Luterstein E, DeRose YS, Welm A, Cheresh DA, Desgrosellier JS. Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis. The Journal of Clinical Investigation. 128: 531-544. PMID 29227280 DOI: 10.1172/Jci93707 |
0.569 |
|
| 2018 |
Lai SCA, Ekiz A, Welm A. Abstract A30: Ron kinase inhibition to improve immunotherapy for breast cancer metastasis Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A30 |
0.614 |
|
| 2017 |
Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, ... ... Welm A, et al. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Research. 77: e62-e66. PMID 29092942 DOI: 10.1158/0008-5472.Can-17-0582 |
0.373 |
|
| 2017 |
Feng Q, Zhang C, Lum D, Druso JE, Blank B, Wilson KF, Welm A, Antonyak MA, Cerione RA. A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis. Nature Communications. 8: 14450. PMID 28205552 DOI: 10.1038/Ncomms14450 |
0.445 |
|
| 2017 |
Andrade K, Fornetti J, Zhao L, Miller SC, Randall RL, Anderson N, Waltz SE, McHale M, Welm AL. RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis. Science Translational Medicine. 9. PMID 28123075 DOI: 10.1126/Scitranslmed.Aai9338 |
0.651 |
|
| 2017 |
Faham N, Welm AL. RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers. Cold Spring Harbor Symposia On Quantitative Biology. PMID 28057847 DOI: 10.1101/sqb.2016.81.031377 |
0.527 |
|
| 2017 |
Takahashi N, Chen H, Harris I, Stover D, Bronson R, Deraedt T, Cichowski K, Welm A, Mills G, Brugge J. Abstract 5478: The TRPA1 Ca2+-permeable channel mediates a non-canonical redox adaptation in cancer cells Cancer Research. 77: 5478-5478. DOI: 10.1158/1538-7445.Am2017-5478 |
0.516 |
|
| 2017 |
Dhimolea E, Simoes RDM, DeRose Y, Awate P, Weng X, Tang H, Culhane A, Welm A, Mitsiades C. Abstract 5016: High-throughput patient-derived 3-dimensional organoid cultures as personalized models to assess drug response and post-treatment residual disease Cancer Research. 77: 5016-5016. DOI: 10.1158/1538-7445.Am2017-5016 |
0.429 |
|
| 2017 |
Palomeras S, Díaz Lagares Á, Blancafort A, Sarrats A, Crujeiras Martinez A, Sandoval J, Rabionet M, Welm A, Esteller M, Puig T. DNA methylation signature to identify trastuzumab response in HER2 breast cancer models Annals of Oncology. 28: i12. DOI: 10.1093/Annonc/Mdx138.010 |
0.35 |
|
| 2017 |
DeVette C, Can I, Ekiz A, Welm A, Hildebrand WH. O43 Therapeutic vaccination against breast cancer in a transgenic mouse model Human Immunology. 78: 40. DOI: 10.1016/J.Humimm.2017.06.049 |
0.411 |
|
| 2016 |
Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, ... ... Welm A, et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Reviews. PMID 28025748 DOI: 10.1007/S10555-016-9653-X |
0.473 |
|
| 2016 |
Olsen SN, Wronski A, Castaño Z, Dake B, Malone C, De Raedt T, Enos M, DeRose YS, Zhou W, Guerra S, Loda M, Welm A, Partridge AH, McAllister SS, Kuperwasser C, et al. Loss of RasGAP Tumor Suppressors Underlie the Aggressive Nature of Luminal B Breast Cancers. Cancer Discovery. PMID 27974415 DOI: 10.1158/2159-8290.Cd-16-0520 |
0.514 |
|
| 2016 |
Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, ... ... Welm AL, et al. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell. PMID 27641504 DOI: 10.1016/j.cell.2016.08.041 |
0.463 |
|
| 2016 |
Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC, Ding WQ. Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Research : Bcr. 18: 90. PMID 27608715 DOI: 10.1186/S13058-016-0753-X |
0.43 |
|
| 2016 |
Moxley KM, Wang L, Welm AL, Bieniasz M. Short-form Ron is a novel determinant of ovarian cancer initiation and progression. Genes & Cancer. 7: 169-81. PMID 27551332 DOI: 10.18632/genesandcancer.109 |
0.486 |
|
| 2016 |
Dennison JB, Shahmoradgoli M, Liu W, Ju Z, Meric-Bernstam F, Perou CM, Sahin A, Welm AL, Oesterreich S, Sikora MJ, Brown RE, Mills GB. High intra-tumoral stromal content defines Reactive breast cancer as a low-risk breast cancer subtype. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27172895 DOI: 10.1158/1078-0432.Ccr-16-0171 |
0.551 |
|
| 2016 |
Giró-Perafita A, Palomeras S, Lum D, Blancafort A, Viñas G, Oliveras G, Pérez-Bueno F, Sarrats A, Welm AL, Puig T. Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple Negative Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27106068 DOI: 10.1158/1078-0432.CCR-15-3133 |
0.417 |
|
| 2016 |
DeVette C, Kaabinejadian S, Fujita M, Hildebrand W, Welm A. OR10 Tumor antigens presented by the HLA-A*02:01 of breast cancer patient-derived xenografts Human Immunology. 77: 9. DOI: 10.1016/J.Humimm.2016.07.022 |
0.509 |
|
| 2015 |
Bieniasz M, Radhakrishnan P, Faham N, De La O JP, Welm AL. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 5588-600. PMID 26289070 DOI: 10.1158/1078-0432.CCR-14-3283 |
0.446 |
|
| 2015 |
Shen L, O'Shea JM, Kaadige MR, Cunha S, Wilde BR, Cohen AL, Welm AL, Ayer DE. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proceedings of the National Academy of Sciences of the United States of America. 112: 5425-30. PMID 25870263 DOI: 10.1073/Pnas.1501555112 |
0.352 |
|
| 2014 |
Chaturvedi A, Hoffman LM, Jensen CC, Lin YC, Grossmann AH, Randall RL, Lessnick SL, Welm AL, Beckerle MC. Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma. Molecular Biology of the Cell. 25: 2695-709. PMID 25057021 DOI: 10.1091/Mbc.E14-01-0007 |
0.329 |
|
| 2014 |
Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, Davidson NE, Dabbs DJ, Welm AL, Oesterreich S. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Research. 74: 1463-74. PMID 24425047 DOI: 10.1158/0008-5472.CAN-13-2779 |
0.355 |
|
| 2014 |
Cunha S, Lin YC, Goossen EA, DeVette CI, Albertella MR, Thomson S, Mulvihill MJ, Welm AL. The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming. Cell Reports. 6: 141-54. PMID 24388747 DOI: 10.1016/j.celrep.2013.12.010 |
0.471 |
|
| 2013 |
Eyob H, Ekiz HA, Welm AL. RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses. Oncoimmunology. 2: e25670. PMID 24327933 DOI: 10.4161/Onci.25670 |
0.765 |
|
| 2013 |
Eyob H, Ekiz HA, Derose YS, Waltz SE, Williams MA, Welm AL. Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. Cancer Discovery. 3: 751-60. PMID 23612011 DOI: 10.1158/2159-8290.Cd-12-0480 |
0.756 |
|
| 2013 |
Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP, Swarbrick A, Welm AL, Brown MP, Chenevix-Trench G, Lakhani SR, Khanna KK. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 913-21. PMID 23564760 DOI: 10.2967/jnumed.112.111534 |
0.362 |
|
| 2013 |
DeRose YS, Gligorich KM, Wang G, Georgelas A, Bowman P, Courdy SJ, Welm AL, Welm BE. Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. Current Protocols in Pharmacology / Editorial Board, S.J. Enna (Editor-in-Chief) ... [Et Al.]. Unit14.23. PMID 23456611 DOI: 10.1002/0471141755.ph1423s60 |
0.414 |
|
| 2013 |
Radhakrishnan P, Bieniasz M, Welm A. Abstract B053: Phosphatidylinositol 3 kinase (PI3K) inhibitors as therapeutic agents for breast tumors overexpressing sfRon Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-B053 |
0.609 |
|
| 2013 |
Faham N, Bieniasz M, Welm A. Abstract A129: Contributions of RON downstream signaling to breast cancer progression Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A129 |
0.556 |
|
| 2013 |
Welm A. Abstract IA14: Inhibition of Ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-Ia14 |
0.623 |
|
| 2013 |
Sikora M, Cooper K, Bahreini A, Luthra S, Chandran U, Wang G, Dabbs D, Welm A, Oesterreich S. Abstract P5-09-03: Endocrine response in invasive lobular carcinoma is characterized by unique estrogen-mediated gene expression and de novo tamoxifen resistance Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P5-09-03 |
0.388 |
|
| 2012 |
Lum DH, Matsen C, Welm AL, Welm BE. Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research. Current Protocols in Pharmacology / Editorial Board, S.J. Enna (Editor-in-Chief) ... [Et Al.]. Unit 14.22. PMID 23258598 DOI: 10.1002/0471141755.ph1422s59 |
0.344 |
|
| 2012 |
Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL, Beckerle MC. The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma. Genes & Cancer. 3: 102-16. PMID 23050043 DOI: 10.1177/1947601912457024 |
0.353 |
|
| 2012 |
Larrieu-Lahargue F, Welm AL, Bouchecareilh M, Alitalo K, Li DY, Bikfalvi A, Auguste P. Blocking Fibroblast Growth Factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis. Plos One. 7: e39540. PMID 22761819 DOI: 10.1371/Journal.Pone.0039540 |
0.31 |
|
| 2012 |
Kretschmann KL, Welm AL. Mouse models of breast cancer metastasis to bone. Cancer Metastasis Reviews. 31: 579-83. PMID 22706780 DOI: 10.1007/s10555-012-9378-4 |
0.416 |
|
| 2012 |
Sikora M, Luthra S, Chandran U, Dabbs D, Welm A, Oesterreich S. Abstract P6-04-20: Endocrine resistance in invasive lobular carcinoma cells parallels unique estrogen-mediated gene expression Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P6-04-20 |
0.466 |
|
| 2011 |
Liu X, Zhao L, Derose YS, Lin YC, Bieniasz M, Eyob H, Buys SS, Neumayer L, Welm AL. Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase. Genes & Cancer. 2: 753-62. PMID 22207901 DOI: 10.1177/1947601911421924 |
0.778 |
|
| 2011 |
DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nature Medicine. 17: 1514-20. PMID 22019887 DOI: 10.1038/nm.2454 |
0.448 |
|
| 2011 |
Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS. Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Research. 71: 5579-87. PMID 21700716 DOI: 10.1158/0008-5472.Can-11-0458 |
0.482 |
|
| 2011 |
Cunha S, Welm A. Abstract 2420: Role of epigenetic modifications in RON/MSP induced breast cancer metastasis Cancer Research. 71: 2420-2420. DOI: 10.1158/1538-7445.Am2011-2420 |
0.625 |
|
| 2011 |
Chaturvedi AP, Welm A, Lessnick S, Beckerle M. Abstract 2366: Impact of EWS-FLI induced changes in gene expression and cell behavior on metastatic potential Cancer Research. 71: 2366-2366. DOI: 10.1158/1538-7445.Am2011-2366 |
0.394 |
|
| 2011 |
Kretschmann* K, Waltz S, Welm A. The role of macrophage stimulating protein in metastasis of breast cancer to bone Bone. 48: S18. DOI: 10.1016/j.bone.2010.10.046 |
0.463 |
|
| 2010 |
Kretschmann KL, Eyob H, Buys SS, Welm AL. The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression. Current Drug Targets. 11: 1157-68. PMID 20545605 DOI: 10.2174/138945010792006825 |
0.777 |
|
| 2010 |
Kim S, Welm AL, Bishop JM. A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis. Cancer Research. 70: 5155-62. PMID 20501848 DOI: 10.1158/0008-5472.Can-10-0425 |
0.46 |
|
| 2010 |
Larrieu-Lahargue F, Welm AL, Thomas KR, Li DY. Netrin-4 induces lymphangiogenesis in vivo. Blood. 115: 5418-26. PMID 20407033 DOI: 10.1182/blood-2009-11-252338 |
0.313 |
|
| 2010 |
Gilbert PM, Mouw JK, Unger MA, Lakins JN, Gbegnon MK, Clemmer VB, Benezra M, Licht JD, Boudreau NJ, Tsai KK, Welm AL, Feldman MD, Weber BL, Weaver VM. HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. The Journal of Clinical Investigation. 120: 1535-50. PMID 20389018 DOI: 10.1172/Jci39534 |
0.453 |
|
| 2009 |
Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Barón AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford HL. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. The Journal of Clinical Investigation. 119: 2678-90. PMID 19726885 DOI: 10.1172/Jci37815 |
0.398 |
|
| 2009 |
McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. The Journal of Clinical Investigation. 119: 2663-77. PMID 19726883 DOI: 10.1172/Jci37691 |
0.375 |
|
| 2009 |
Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2311-22. PMID 19318475 DOI: 10.1158/1078-0432.Ccr-08-2533 |
0.313 |
|
| 2008 |
Welm AL. TGFbeta primes breast tumor cells for metastasis. Cell. 133: 27-8. PMID 18394984 DOI: 10.1016/j.cell.2008.03.012 |
0.413 |
|
| 2007 |
Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH, Bishop JM. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proceedings of the National Academy of Sciences of the United States of America. 104: 7570-5. PMID 17456594 DOI: 10.1073/Pnas.0702095104 |
0.511 |
|
| 2007 |
Bhatt AS, Welm A, Farady CJ, Vásquez M, Wilson K, Craik CS. Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proceedings of the National Academy of Sciences of the United States of America. 104: 5771-6. PMID 17389401 DOI: 10.1073/Pnas.0606514104 |
0.452 |
|
| 2007 |
Bhatt AS, Welm A, Vásquez M, Wilson K, Craik CS. Using Coordinate Expression and Functional Profiling to Identify an Extracellular Proteolytic Signaling Pathway The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A249-C |
0.301 |
|
| 2005 |
Welm AL, Kim S, Welm BE, Bishop JM. MET and MYC cooperate in mammary tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 102: 4324-9. PMID 15738393 DOI: 10.1073/pnas.0500470102 |
0.484 |
|
| 2004 |
Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proceedings of the National Academy of Sciences of the United States of America. 101: 15100-5. PMID 15477601 DOI: 10.1073/Pnas.0406665101 |
0.312 |
|
| 2004 |
Welm AL. AACR Special Conference: Advances in Breast Cancer Research--Genetics, Biology, and Clinical Implications, Huntington Beach, California, USA, 8-12 October 2003. Breast Cancer Research : Bcr. 6: E6. PMID 14680491 DOI: 10.1186/bcr747 |
0.368 |
|
| Show low-probability matches. |